Oruka Therapeutics jumps 65% on psoriasis drug trial momentum

Oruka Therapeutics shares climbed 65% in three months as Phase IIa data showed 63.5% of psoriasis patients achieved complete skin clearance on lead candidate ORKA-001, setting up a Phase III launch in 2027.

The rally was "primarily driven by growing investor confidence in the company's lead asset, ORKA-001, and broader clinical progress," Zacks Investment Research said. The stock trades at $96.54, against a 1-year consensus target of $153.75, implying roughly 59% upside.

The Phase IIa EVERLAST-A study showed 83% of participants achieved PASI 90 and 84% reached IGA 0/1 at week 16, with a safety profile consistent with the IL-23p19 class. The 65% gain compares with a 12.8% rise for the broader industry over the same period. Oruka completed enrollment in the Phase IIb EVERLAST-B dose-ranging study and expects week 16 data in the fourth quarter of 2026. The company also initiated ORCA-SPLASH, a Phase II study of ORKA-002 in hidradenitis suppurativa, and expects week 16 data from the ORCA-SURGE psoriasis study in the first quarter of 2027.

Oruka holds $873.6 million in cash against a $6.2 billion market cap, with a 52-week range of $14.61 to $115.52. The company plans to launch Phase III psoriasis trials in the first half of 2027 and expects ORKA-004, a TL1A-targeting antibody, to enter clinical development in the fourth quarter of 2026. Positive readouts across these programs could sustain momentum, while any setback would expose the shares to sharp downside after the 65% run-up.

ORKA-001 Data Sets the Bar in a Crowded Psoriasis Market

The IL-23p19 inhibitor class is among the most competitive in dermatology. Johnson & Johnson's Tremfya and AbbVie's Skyrizi both target the same pathway and generated combined sales exceeding $10 billion in 2025. ORKA-001's 63.5% PASI 100 rate at week 16 compares favorably with published data for Skyrizi, which showed approximately 57% PASI 100 at week 16 in its pivotal trials. The half-life extension technology behind ORKA-001 could enable annual or semiannual dosing, a differentiation that would address a key adherence problem in chronic psoriasis care.

Oruka expects week 28 data from EVERLAST-A in the third quarter of 2026, followed by 52-week data in December. These readouts will provide evidence on durability and inform the dosing interval question. The Phase IIb EVERLAST-B study, with week 16 data due in the fourth quarter, will guide dose selection for the Phase III program.

Pipeline Expansion Beyond Psoriasis

ORKA-002, a half-life-extended IL-17A/F antibody, targets a different inflammatory pathway and could broaden Oruka's addressable market. The Phase II ORCA-SPLASH study in hidradenitis suppurativa, a chronic skin condition with limited treatment options, represents a meaningful expansion beyond psoriasis. UCB's Bimzelx, the only approved IL-17A/F inhibitor, generated $1.2 billion in 2025 sales, providing a reference point for ORKA-002's commercial potential.

ORKA-004, targeting TL1A, is expected to enter clinical development in the fourth quarter of 2026, with Phase II combination studies planned for 2027. The combination strategy — pairing TL1A blockade with IL-23 or IL-17 inhibition — mirrors approaches being explored by larger players in inflammatory disease.

Oruka trades at a $6.2 billion market cap with no revenue, meaning the stock's value rests entirely on clinical execution. The $873.6 million cash position provides runway through multiple data readouts, but the 65% rally has priced in substantial success. Investors will need to weigh the potential of annual dosing against the execution risk inherent in a company with three clinical-stage programs and no approved products. The next major data readout is the week 28 EVERLAST-A results in the third quarter of 2026.

This article is for informational purposes only and does not constitute investment advice.